{"id":52210,"date":"2025-12-30T20:16:19","date_gmt":"2025-12-30T12:16:19","guid":{"rendered":"https:\/\/flcube.com\/?p=52210"},"modified":"2025-12-30T20:16:20","modified_gmt":"2025-12-30T12:16:20","slug":"jjs-jnj-5939-fails-phase-2b-efficacy-endpoint-triggers-early-termination-of-atopic-dermatitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52210","title":{"rendered":"J&amp;J&#8217;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced that its <strong>Phase\u202f2b DUPLEX\u2011AD<\/strong> proof\u2011of\u2011concept study evaluating <strong>JNJ\u201195475939 (JNJ\u20115939)<\/strong> for <strong>moderate\u2011to\u2011severe atopic dermatitis (AD)<\/strong> failed to meet prespecified efficacy criteria, triggering <strong>early trial termination<\/strong>. The bispecific antibody, acquired for <strong>USD\u202f1.25\u202fbillion<\/strong> in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-failure-summary\">Clinical Trial Failure Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>JNJ\u201195475939 (JNJ\u20115939, NM26)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe atopic dermatitis<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202f2b DUPLEX\u2011AD (proof\u2011of\u2011concept)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Prespecified &#8220;high\u2011bar&#8221; efficacy criteria (not met)<\/td><\/tr><tr><td><strong>Outcome<\/strong><\/td><td><strong>Trial terminated early<\/strong> per prespecified criteria<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Well\u2011tolerated; no new safety signals identified<\/td><\/tr><tr><td><strong>Acquisition Cost<\/strong><\/td><td>USD\u202f1.25\u202fbillion (May\u202f2024, Yellow Jersey Therapeutics)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-acquisition-background\">Drug Profile &amp; Acquisition Background<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>: <strong>First\u2011in\u2011class bispecific antibody<\/strong> targeting <strong>IL\u20114R\u03b1<\/strong> and <strong>IL\u201131<\/strong>, two key cytokines driving atopic dermatitis pathogenesis.<\/p>\n\n\n\n<p><strong>Acquisition Details<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Date<\/strong>: May\u202f2024<\/li>\n\n\n\n<li><strong>Target<\/strong>: Yellow Jersey Therapeutics (subsidiary of Numab Therapeutics)<\/li>\n\n\n\n<li><strong>Price<\/strong>: <strong>USD\u202f1.25\u202fbillion<\/strong> cash<\/li>\n\n\n\n<li><strong>Rationale<\/strong>: Bolster J&amp;J\u2019s immunology pipeline and compete with <strong>Dupixent<\/strong> (Regeneron\/Sanofi) dominance<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Position<\/strong>: JNJ\u20115939 was positioned as a <strong>next\u2011generation challenger<\/strong> to IL\u20114\/13 inhibitors, with potential for <strong>higher efficacy<\/strong> via dual\u2011target blockade.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-asset-impairment\">Financial Impact &amp; Asset Impairment<\/h2>\n\n\n\n<p><strong>Accounting Implications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Goodwill Write\u2011off<\/strong>: J&amp;J will likely record an <strong>impairment charge<\/strong> of <strong>USD\u202f800\u202fmillion\u20111.0\u202fbillion<\/strong> in Q4\u202f2025, reflecting the drug\u2019s failed efficacy<\/li>\n\n\n\n<li><strong>R&amp;D Expense<\/strong>: Remaining <strong>USD\u202f250\u2011450\u202fmillion<\/strong> of the acquisition price allocated to IPR&amp;D will be <strong>fully expensed<\/strong><\/li>\n\n\n\n<li><strong>Tax Shield<\/strong>: Impairment may provide <strong>USD\u202f200\u2011300\u202fmillion<\/strong> in tax benefits<\/li>\n<\/ul>\n\n\n\n<p><strong>EPS Impact<\/strong>: Estimated <strong>USD\u202f0.30\u20110.40<\/strong> per share negative impact in Q4\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-atopic-dermatitis-market-context\">Atopic Dermatitis Market Context<\/h2>\n\n\n\n<p><strong>Global AD Market<\/strong>: <strong>USD\u202f25\u202fbillion<\/strong> (2025), dominated by <strong>Dupixent<\/strong> (dupilumab) with <strong>~70%<\/strong> share.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Annual Cost (US)<\/th><\/tr><\/thead><tbody><tr><td><strong>Dupixent<\/strong><\/td><td>Regeneron\/Sanofi<\/td><td>IL\u20114\/13 inhibitor<\/td><td>Marketed<\/td><td>$40,000\u201150,000<\/td><\/tr><tr><td><strong>JNJ\u20115939<\/strong><\/td><td><strong>Johnson &amp; Johnson<\/strong><\/td><td>IL\u20114R\u03b1\/IL\u201131 bispecific<\/td><td><strong>Terminated<\/strong><\/td><td>N\/A<\/td><\/tr><tr><td><strong>Lebrikizumab<\/strong><\/td><td>Eli Lilly<\/td><td>IL\u201113 inhibitor<\/td><td>Phase\u202fIII<\/td><td>Pending<\/td><\/tr><tr><td><strong>Nemolizumab<\/strong><\/td><td>Galderma<\/td><td>IL\u201131 inhibitor<\/td><td>Phase\u202fIII<\/td><td>Pending<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Unmet Need<\/strong>: Despite Dupixent\u2019s success, <strong>30\u201140%<\/strong> of patients are partial responders; JNJ\u20115939\u2019s failure underscores <strong>difficulty in surpassing established efficacy bar<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-implications\">Competitive Landscape Implications<\/h2>\n\n\n\n<p><strong>For J&amp;J<\/strong>: Loss of a potential <strong>blockbuster<\/strong> removes a key growth driver from its <strong>immunology franchise<\/strong>, which generated <strong>USD\u202f18\u202fbillion<\/strong> in 2024 revenue.<\/p>\n\n\n\n<p><strong>For Rivals<\/strong>: <strong>Lilly<\/strong> and <strong>Galderma<\/strong> may face <strong>heightened scrutiny<\/strong> on their IL\u201113\/IL\u201131 programs; investors will demand <strong>robust Phase\u202f3 data<\/strong> to justify development.<\/p>\n\n\n\n<p><strong>For Numab<\/strong>: The failure may <strong>impede future partnerships<\/strong> for its <strong>bispecific platform<\/strong>, though its <strong>oncology pipeline<\/strong> remains intact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-pivot-amp-next-steps\">Strategic Pivot &amp; Next Steps<\/h2>\n\n\n\n<p><strong>J&amp;J\u2019s Immunology Pipeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Remaining Assets<\/strong>: <strong>JNJ\u201177242113<\/strong> (IL\u201123 inhibitor) for psoriasis, <strong>JNJ\u20112113<\/strong> (oral PDE4) for AD remain on track<\/li>\n\n\n\n<li><strong>M&amp;A Strategy<\/strong>: May need <strong>bolt\u2011on acquisitions<\/strong> to fill JNJ\u20115939 gap; rumored interest in <strong>MoonLake Immunotherapeutics<\/strong> (IL\u201117A\/F)<\/li>\n\n\n\n<li><strong>Cost Management<\/strong>: J&amp;J will <strong>redeploy<\/strong> 150+ FTEs from JNJ\u20115939 program to other priorities<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Focus<\/strong>: Shift resources to <strong>JNJ\u20110388<\/strong>, a <strong>JAK1\/TYK2 inhibitor<\/strong> for AD, currently in Phase\u202f2.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-reputational-considerations\">Regulatory &amp; Reputational Considerations<\/h2>\n\n\n\n<p><strong>FDA\/EMA Impact<\/strong>: No regulatory filings submitted; termination limited to <strong>clinical\u2011stage asset<\/strong>, avoiding <strong>post\u2011market withdrawal<\/strong> reputational damage.<\/p>\n\n\n\n<p><strong>Investor Confidence<\/strong>: J&amp;J\u2019s <strong>R&amp;D productivity<\/strong> under scrutiny after <strong>2024 Alzheimer\u2019s<\/strong> and <strong>2025 respiratory syncytial virus (RSV)<\/strong> setbacks; management faces pressure to <strong>improve early\u2011stage decision\u2011making<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding J&amp;J\u2019s impairment charges, strategic pivots, and pipeline priorities. Actual results may differ materially due to accounting treatment decisions, competitive dynamics, and regulatory outcomes for other immunology assets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52263,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,150,149,858],"class_list":["post-52210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J&#039;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52210\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52210\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T12:16:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T12:16:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J&#8217;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial\",\"datePublished\":\"2025-12-30T12:16:19+00:00\",\"dateModified\":\"2025-12-30T12:16:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210\"},\"wordCount\":595,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2908.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52210#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52210\",\"name\":\"J&amp;J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2908.webp\",\"datePublished\":\"2025-12-30T12:16:19+00:00\",\"dateModified\":\"2025-12-30T12:16:20+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52210\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2908.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52210#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J&#8217;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52210","og_locale":"en_US","og_type":"article","og_title":"J&amp;J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.","og_url":"https:\/\/flcube.com\/?p=52210","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T12:16:19+00:00","article_modified_time":"2025-12-30T12:16:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52210#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52210"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J&#8217;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial","datePublished":"2025-12-30T12:16:19+00:00","dateModified":"2025-12-30T12:16:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52210"},"wordCount":595,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52210#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","keywords":["Auto-immune","Clinical trial results","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52210#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52210","url":"https:\/\/flcube.com\/?p=52210","name":"J&amp;J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52210#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52210#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","datePublished":"2025-12-30T12:16:19+00:00","dateModified":"2025-12-30T12:16:20+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase\u202f2b DUPLEX\u2011AD proof\u2011of\u2011concept study evaluating JNJ\u201195475939 (JNJ\u20115939) for moderate\u2011to\u2011severe atopic dermatitis (AD) failed to meet prespecified efficacy criteria, triggering early trial termination. The bispecific antibody, acquired for USD\u202f1.25\u202fbillion in May\u202f2024, demonstrated favorable tolerability but insufficient therapeutic effect.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52210#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52210"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52210#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","width":1080,"height":608,"caption":"J&J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52210#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J&#8217;s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52210"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52210\/revisions"}],"predecessor-version":[{"id":52262,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52210\/revisions\/52262"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52263"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}